Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Developer of a digital therapy platform intended to provide life-saving treatments. The company's platform features a chatbot that goes back and forth with users to gather specific issues and develop a course of exercises and information tailored for individual needs along with a variety of animated explanations, videos based on real-life examples and other digital resources, enabling people to tackle suicide and other challenging health care problems.
CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
Tessa Therapeutics Pte Ltd. is a biotechnology company focused on developing innovative cancer immunotherapies, specifically targeting solid tumors. Founded in 2011 and based in Singapore, the company specializes in creating virus-specific T cells and CAR T cells aimed at treating lymphoma. By advancing these therapies, Tessa Therapeutics seeks to provide healthcare providers with effective options to improve the lives of cancer patients.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
Sonrai Security Inc. offers an enterprise identity and data governance platform designed for cloud and security teams, focusing on AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform utilizes a sophisticated graph to identify and monitor relationships between identities and data within an organization's public cloud. This enables security and DevOps leaders to address data threats, ensure compliance, and enhance operational efficiency. The platform includes a Governance Automation Engine that streamlines workflows, remediation, and preventive measures across cloud and security teams. Founded in 2017 and headquartered in New York, Sonrai Security serves a diverse range of sectors, including education, financial services, healthcare, and telecommunications, among others.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.
ByHeart, Inc. is an infant nutrition company that develops a range of nutritional food products for infants and babies, focusing on immune, microbiome, cognitive, and digestive health. Founded in 2016 and headquartered in New York, the company operates facilities in Pennsylvania. ByHeart emphasizes the use of hand-picked ingredients and small-batch blending to create formulas that reflect the latest in nutrition science and breastmilk research. Their products are designed to support babies' health and provide parents with peace of mind, offering choices that help establish a strong foundation for future well-being.
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
CubicPV is a solar industry that relies on legacy technologies with inherent limitations. Conventional solar modules convert sunlight to electricity using a single light-absorbing material and are nearing an efficiency threshold.
Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families in managing the complexities of care for chronically ill, aging, or disabled loved ones. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative tasks associated with caregiving. Their platform enables families to track appointments, organize tasks, store important documents, and maintain communication. Wellthy addresses various needs beyond medical care, including legal, financial, housing, and emotional support. The service is designed to alleviate the burden of caregiving by taking on tasks such as making calls, scheduling appointments, and managing paperwork. Additionally, Wellthy partners with employers to offer a compassionate and scalable solution to support families dealing with aging-related issues, childcare, special needs, and other ongoing care challenges.
Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.
CAMP4 Therapeutics Corporation is a bioinformatics company based in Cambridge, Massachusetts, founded in 2015. The company specializes in gene regulation circuitry, utilizing a 4-D gene circuitry platform to codify the activation of the over 24,000 genes in the human body into a set of combinatorial rules. This approach allows CAMP4 to manipulate gene production through existing cellular signaling pathways, directly addressing the fundamental causes of diseases. By leveraging machine learning algorithms, the platform simplifies the drug discovery process, enabling the identification of druggable targets and facilitating a quicker and less risky path to developing new medicines. This innovative methodology significantly accelerates the initiation of disease treatment, ultimately benefiting patients by reducing the time required to bring new therapies to market.
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of innovative treatments for serious and orphan diseases. The company focuses on soluble guanylate cyclase (sGC) pharmacology to harness the therapeutic potential of next-generation sGC stimulators. Its key product candidates include Olinciguat, which is undergoing Phase II studies for sickle cell disease, and Praliciguat, currently in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction. Additionally, Cyclerion is developing IW-6463, an orally administered central nervous system-penetrant sGC stimulator in Phase I trials aimed at treating neurodegenerative diseases. The company is also exploring liver-targeted and lung-targeted sGC stimulators to expand its therapeutic offerings. Cyclerion Therapeutics was incorporated in 2018 and is dedicated to addressing unmet medical needs through its innovative pipeline.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
PMI BioPharma Solutions is providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.
Engine Biosciences Pte. Ltd. is a biotechnology company that specializes in drug discovery by leveraging machine learning and genomics. Founded in 2014 and based in Singapore, the company has developed a validated platform that integrates high-throughput wet lab experimentation with artificial intelligence algorithms. This unique approach enables the mapping and analysis of complex biological networks and gene interactions, facilitating the identification of disease-driving errors. The platform supports researchers and drug developers in various aspects of drug discovery, including target discovery, drug repositioning, and pathway analysis. Engine Biosciences collaborates with American Fortune 500 companies and research institutions, aiming to accelerate and reduce the costs associated with the research and development process for new medical therapies. The company’s leadership team includes experts from renowned institutions such as MIT, Harvard, Mayo Clinic, and UCSD.
Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Cohere Health, Inc. is a software-as-a-service company based in Boston, Massachusetts, that focuses on enhancing the healthcare experience for patients, providers, and health plans. Incorporated in 2019, the company aims to improve the quality of care while reducing overall costs and increasing transparency throughout the patient care journey. Cohere Health specializes in intelligent prior authorization services, which are tailored to meet the specific needs of different health plans. By leveraging artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process and facilitates collaboration between physicians and health plans. This approach not only streamlines the utilization management service but also promotes quality care across the entire patient journey.
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
Tausight, Inc. develops a software for reducing healthcare cyber incidents of patient data theft. It serves chief information officer of health care sector. Tausight was founded in 2018 and is based in Sudbury, Massachusetts with additional office in San Francisco, California.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Developed by spine specialists, the SpineZone Method relieves long-term back and neck injuries without resorting to invasive procedures
Armorblox, Inc., founded in 2017 and headquartered in Cupertino, California, specializes in data security solutions that focus on safeguarding the human layer of organizations. The company utilizes advanced techniques in machine learning and artificial intelligence to protect against identity-based attacks and prevent data loss. As a venture-backed startup, Armorblox aims to enhance cybersecurity measures for businesses through innovative technology.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
B2Gnow specializes in developing software solutions aimed at enhancing diversity management and compliance for corporations, contractors, institutions, and government sectors. Their turn-key, hosted software automates various processes, including data gathering, tracking, reporting, and vendor management. By streamlining these administrative functions, B2Gnow enables organizations to save 60%-80% of the time typically spent on clerical activities, allowing them to concentrate on achieving their diversity objectives more effectively. The company's solutions not only reduce operational costs but also improve the overall impact and reach of diversity initiatives.
Automotive Titling Company, LLC specializes in vehicle title and registration services tailored for the automotive industry. Founded in 1972 and located in Centennial, Colorado, the company serves auto dealers, fleet managers, and financial institutions. It aids dealers in streamlining the vehicle sale process, particularly for transactions that occur across state lines. The company provides essential services such as offering guidance on taxes, fees, and title requirements, auditing paperwork, and managing the necessary forms and filings through established contacts. By facilitating these processes, Automotive Titling Company enables its clients to efficiently handle interstate vehicle sales and enhance their sales volume. The company changed its name from Automotive Titling of Colorado, Inc. in November 2020.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
Developer of veterinary practice management software intended to empower veterinary practice partners to drive improved health and financial outcomes. The company's services include supply chain services, software services and prescription management, intended for the well-being of animals and those who care for them drives to advance the world of veterinary medicine.
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Sesh Therapy Incorporated is a mental health company that delivers online group support through its mobile application. Founded in 2020 and headquartered in San Francisco, California, Sesh provides a range of sessions led by qualified mental health professionals, making mental healthcare more accessible and affordable compared to traditional therapy appointments. The platform aims to connect individuals seeking support in a collaborative environment, enhancing the overall mental health experience.
Automotive Titling Company, LLC specializes in vehicle title and registration services tailored for the automotive industry. Founded in 1972 and located in Centennial, Colorado, the company serves auto dealers, fleet managers, and financial institutions. It aids dealers in streamlining the vehicle sale process, particularly for transactions that occur across state lines. The company provides essential services such as offering guidance on taxes, fees, and title requirements, auditing paperwork, and managing the necessary forms and filings through established contacts. By facilitating these processes, Automotive Titling Company enables its clients to efficiently handle interstate vehicle sales and enhance their sales volume. The company changed its name from Automotive Titling of Colorado, Inc. in November 2020.
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
The One Health Company is a social impact company that brings precision medicine, used in humans, to dogs with cancer.
It started by offering dogs with cancer access to cutting edge human clinical trials at no cost. Then, they created FidoCure directly for veterinarians and pet parents to offer treatment options to more dogs across the country. The company built partnerships with the world's top cancer researchers and a network of 111 of the best veterinary hospitals.
Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.
Sonrai Security Inc. offers an enterprise identity and data governance platform designed for cloud and security teams, focusing on AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform utilizes a sophisticated graph to identify and monitor relationships between identities and data within an organization's public cloud. This enables security and DevOps leaders to address data threats, ensure compliance, and enhance operational efficiency. The platform includes a Governance Automation Engine that streamlines workflows, remediation, and preventive measures across cloud and security teams. Founded in 2017 and headquartered in New York, Sonrai Security serves a diverse range of sectors, including education, financial services, healthcare, and telecommunications, among others.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
ARInsights, LLC develops cloud based analyst relationship management software solutions. The company offers a software as a service (SaaS) based platform, ARchitect, which provides relationship management and workflow modules for analyst relations. It also provides ARchitect event manager, ARchitect portal, ARchitect database, ARchitect Relationship Manager, ARchitect Emailer, ARchitect mobile application, ARchitect Reporting, ARchitect Analyst Grouping, and ARchitect Briefing Book tools and plug-ins. In addition, the company provides ServicePlus solutions for strategic planning, project support, administration, and operational assistance services. The company was founded in 2004 and is based in Sunny Isles Beach, Florida.
Neogene Therapeutics, Inc. is a biotechnology company based in New York that focuses on the development of T cell therapies to treat cancer. Founded in 2018, the company specializes in creating personalized engineered T-cells that target neo-antigens, which are mutated proteins resulting from DNA alterations in cancer cells. Neogene's innovative platform allows for the isolation of T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies, which are routinely collected from patients. By utilizing advanced DNA sequencing and genetic screening technologies, Neogene can accurately identify and engineer TCRs that enhance the ability of T-cells to detect and eliminate cancer cells. This approach aims to improve treatment outcomes for cancer patients by providing therapies tailored to their unique tumor profiles.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Private Equity Round in 2020
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.
Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. It specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus includes spinocerebellar ataxias, Huntington's disease, and Rett syndrome, which are characterized by progressive neurological decline and developmental challenges. Vico Therapeutics is committed to discovering and delivering innovative treatments that address the unmet medical needs of patients suffering from these severe conditions. Through its research and development efforts, the company seeks to provide effective therapeutic options for individuals affected by these disorders.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Foresight Mental Health is a technology-enabled company focused on providing comprehensive psychiatry and therapy services. It employs a team of psychiatrists, therapists, and psychiatric nurse practitioners who deliver treatment directly to patients in its clinics. Foresight aims to transform mental healthcare by integrating advanced technology developed by its software and biomedical engineers with clinical practice. The company offers a wide range of mental health treatments and wellness services, utilizing patient profiles that incorporate scientific research, genetic information, and detailed assessments of symptoms and brain chemistry. This holistic approach is designed to enhance patient outcomes, promoting improved mental health and overall well-being.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
ByHeart, Inc. is an infant nutrition company that develops a range of nutritional food products for infants and babies, focusing on immune, microbiome, cognitive, and digestive health. Founded in 2016 and headquartered in New York, the company operates facilities in Pennsylvania. ByHeart emphasizes the use of hand-picked ingredients and small-batch blending to create formulas that reflect the latest in nutrition science and breastmilk research. Their products are designed to support babies' health and provide parents with peace of mind, offering choices that help establish a strong foundation for future well-being.
Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Montis Biosciences is a biotechnology company based in Meise, Belgium, focused on developing immune-oncology therapeutics aimed at addressing the relationship between vascular dysfunction and immune suppression in the treatment of solid tumors. Founded in 2020, the company utilizes a target screening and assay platform to identify and develop therapeutic targets that modify the interactions between tumor endothelial cells and perivascular macrophages.
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Mesodyne's solution is a novel ultra-high energy density, multi-fuel, silent, compact power generator. Our generators convert fuel to electricity with heat and light as intermediaries: a small micro combustor heats a photonic crystal to incandescence and the resulting light is tailored to the bandgap of an infrared cell resulting in unprecedented high efficiencies.
Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses.
The company was founded in 2019 and headquartered in Waltham, Massachusetts.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Allstacks is a predictive, curated Business Intelligence for Software Engineering Managers. It is the leading predictive forecasting and risk management solution for software development. We deliver business outcomes, not just metrics. It was founded by Hersh Tapadia and Jeremy Freeman in 2017 and is based in Raleigh, North Carolina.
Private Equity Round in 2019
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
Recurly, Inc. specializes in providing subscription management and billing solutions designed to optimize revenue growth for businesses across various industries, including digital media, streaming, publishing, SaaS, and consumer goods. Founded in 2009 and headquartered in San Francisco, California, with additional offices in Boulder and New Orleans, the company offers a comprehensive platform that automates recurring billing processes, enhances payment acceptance, and reduces subscriber churn through effective card recycling strategies. Recurly's services allow businesses to quickly implement subscription billing systems, manage customer-related billing issues effortlessly, and gain actionable insights into their operations. As a level 1 PCI compliant service provider, Recurly also helps clients minimize costs and obligations associated with payment security. By streamlining these functions, Recurly enables businesses to focus on growth and improve their overall subscriber economics.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.